NCT01232556 2019-01-08A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyPfizerPhase 3 Terminated338 enrolled 15 charts
NCT00562965 2018-01-09Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)PfizerPhase 3 Terminated29 enrolled 14 charts